Study Of ATRN-119 In Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Aprea Therapeutics (industry) · APRE — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
43actual
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-09 | actual | When the study began enrolling |
| Primary completion | 2026-03-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-09 | actual | The whole study's end, after follow-up |
| First posted | 2021-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Intervention
- Drug: ATRN-119
Primary outcome
what the primary-completion date above is the date OFTreatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics
measured Day 1 to Day 28
Permalink · APRE's whole pipeline · Catalyst calendar · Every registered study · What changed